Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTimizing Treatment Focused Genetic Testing IN Cancer - OPT-IN

NCT04066361 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT04066361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04066361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTimizing Treatment Focused Genetic Testing IN Cancer - OPT-IN
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Completed
Start date
December 19, 2019
Completion date
November 30, 2022
Enrollment
301 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian cancer, pancreatic cancer, prostate cancer